相关实验视频

Updated: Jun 29, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

ZNF397缺乏引发TET2驱动的血统可塑性和AR向性治疗阻力在前列腺癌中

Yaru Xu¹, Yuqiu Yang², Zhaoning Wang^1,3

¹Department of Molecular Biology, UT Southwestern Medical Center, Dallas, Texas.

Cancer discovery

|April 9, 2024

概括

指蛋白397 (ZNF397) 损失驱动前列腺癌血统的可塑性和治疗耐药性. 一个十-十一转位2 (TET2) 抑制剂可以克服这种抵抗,提供一种新的治疗策略.

科学领域:

在瘤学瘤学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
分子生物学分子生物学

背景情况:

癌细胞利用表型可塑性和表观遗传重编程来逃避向治疗.
在癌症中,血统可塑性和治疗耐药性获得的机制仍然不太清楚.

研究的目的:

在前列腺癌中识别血统可塑性和治疗耐药性的机制.
为了研究指蛋白397 (ZNF397) 在雄激素受体 (AR) 驱动前列腺癌中的作用.
探索针对AR向治疗耐药性的治疗策略.

主要方法:

鉴定ZNF397作为雄激素受体 (AR) 的联合激活剂.
研究了ZNF397缺陷在促进血统可塑性方面的作用.
评估了十-十一转位2 (TET2) 抑制剂在克服治疗耐药性的有效性.

主要成果:

ZNF397缺乏促进过渡到一个TET2驱动的血统塑性状态,赋予AR向治疗的耐药性.
一种TET2抑制剂有效地消除了ZNF397缺乏的前列腺瘤的治疗阻力.
发现了一种新的表观遗传机制,驱动前列腺癌血统的可塑性和治疗耐药性.

结论:

ZNF397在调节前列腺癌血统可塑性和治疗反应方面发挥着分开的作用.
一个TET2驱动的表观遗传机制对于瘤适应和抵抗至关重要.
向TET2提供了一个有希望的策略,以克服前列腺癌中AR向治疗的耐药性.

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...